Global Recombinant Therapeutic Antibodies and Proteins Market Report, History and Forecast 2024-2034, Breakdown Data by Companies, Key Regions, Types and Application
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Recombinant Therapeutic Antibodies and Proteins Market Report, History and Forecast 2024-2034, Breakdown Data by Companies, Key Regions, Types and Application
Therapeutic proteins are engineered in the laboratory for pharmaceutical use, including non-covalent binders. These proteins are highly effective and serve as modernized treatment for rare as well as chronic diseases. Protein therapeutics offer custom-made treatment approach by supporting a specifically targeted therapeutic process by compensating the deficiency of an essential protein. Recombinant proteins have gained significant traction for therapeutic applications and the number of proteins either launched or approved into clinical trials has continually increased over the past two decades. According to the National Center for Biotechnology Information (NCBI) data of 2017, the U.S. Food and Drug Administration (FDA) approved over 140 recombinant therapeutic proteins for human use and several hundred are currently in development. Majority of these proteins are recombinant monoclonal antibodies.
Recombinant Therapeutic Antibodies and Proteins report published by Mr Accuracy reports reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Recombinant Therapeutic Antibodies and Proteins market is projected to reach US$ 143680 million in 2034, increasing from US$ 89490 million in 2022, with the CAGR of 6.9% during the period of 2024 to 2034. Demand from Oncology and Hematology are the major drivers for the industry.
The global recombinant therapeutic antibodies and proteins market size was valued at US$ 92.5 billion in 2017, and is expected to witness a robust CAGR of 11.2% over the forecast period (2017 – 2025).
Report Scope
This report, based on historical analysis (2024-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Recombinant Therapeutic Antibodies and Proteins market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Companies, Type, Application and Regions Listed in the Report
Abbott
Amgen
Biogen
Eli Lilly
Roche
Johnson and Johnson
Merck
Novo Nordisk
Pfizer
Sanofi
Segment by Type
Plasma Protein
Fusion Proteins
Monoclonal Antibodies
Hormones
Enzyme
Coagulation Factors
Others
Oncology
Hematology
Immunology
Endocrinology
Infectious Disease
Cardiovascular Disease
Others
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Latin America
Mexico
Brazil
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the Recombinant Therapeutic Antibodies and Proteins market further
Chapter 1Global and regional market size and CAGR for the history and forecast period (2024-2024, 2024-2034).
Chapter 2Product Types and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2024 to 2024.
Chapter 3Product Application and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2024 to 2024.
Chapter 4Company Competition Status, Detailed analysis of Product Name companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5Companies’ Outline, covering company’s basic information, Recombinant Therapeutic Antibodies and Proteins introduction, etc. Recombinant Therapeutic Antibodies and Proteins Revenue and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 6 to 10Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa by revenue.
Chapter 11Market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry.
Chapter 12Mr Accuracy reports’s Conclusions of Recombinant Therapeutic Antibodies and Proteins market based on comprehensive survey.
Chapter 13Methodology and Data Sources adopted by Mr Accuracy reports.
Recombinant Therapeutic Antibodies and Proteins report published by Mr Accuracy reports reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Recombinant Therapeutic Antibodies and Proteins market is projected to reach US$ 143680 million in 2034, increasing from US$ 89490 million in 2022, with the CAGR of 6.9% during the period of 2024 to 2034. Demand from Oncology and Hematology are the major drivers for the industry.
The global recombinant therapeutic antibodies and proteins market size was valued at US$ 92.5 billion in 2017, and is expected to witness a robust CAGR of 11.2% over the forecast period (2017 – 2025).
Report Scope
This report, based on historical analysis (2024-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Recombinant Therapeutic Antibodies and Proteins market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Companies, Type, Application and Regions Listed in the Report
By Company
Abbott
Amgen
Biogen
Eli Lilly
Roche
Johnson and Johnson
Merck
Novo Nordisk
Pfizer
Sanofi
Segment by Type
Plasma Protein
Fusion Proteins
Monoclonal Antibodies
Hormones
Enzyme
Coagulation Factors
Others
Segment by Application
Oncology
Hematology
Immunology
Endocrinology
Infectious Disease
Cardiovascular Disease
Others
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Latin America
Mexico
Brazil
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the Recombinant Therapeutic Antibodies and Proteins market further
Chapter 1Global and regional market size and CAGR for the history and forecast period (2024-2024, 2024-2034).
Chapter 2Product Types and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2024 to 2024.
Chapter 3Product Application and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2024 to 2024.
Chapter 4Company Competition Status, Detailed analysis of Product Name companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5Companies’ Outline, covering company’s basic information, Recombinant Therapeutic Antibodies and Proteins introduction, etc. Recombinant Therapeutic Antibodies and Proteins Revenue and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 6 to 10Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa by revenue.
Chapter 11Market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry.
Chapter 12Mr Accuracy reports’s Conclusions of Recombinant Therapeutic Antibodies and Proteins market based on comprehensive survey.
Chapter 13Methodology and Data Sources adopted by Mr Accuracy reports.
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices